Q-omics provides the consensus-scored VCX profile across patient tissues and cancer cell-line models. VCX expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, VCX is differentially expressed in 10, with the highest sampling consensus in LUSC. Additionally, VCX RNA expression shows 9,295 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LUSC, and THYM as cancer lineages where VCX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VCX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VCX survival associations across molecular data types. VCX RNA expression shows survival associations in the most cancer types (18), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VCX RNA expression–survival associations across cancer types. High VCX expression shows unfavorable associations in KIRC, DLBC, UCEC and LGG, but favorable associations in SCLC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for VCX RNA expression.
This table summarizes VCX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for VCX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VCX shows lower tumor expression in THCA and higher tumor expression in LUSC, LIHC, HNSC, BRCA and KICH. The LUSC box plot shows higher VCX RNA expression in tumor versus normal tissue (log2 FC = +1.044, t-test p < 0.001).
This table shows molecular features associated with VCX in patient tissues and cancer cell lines. In patient samples, VCX shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, VCX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
